Back to Medical Hub

Allergic Rhinitis: Immunotherapy Protocol (PSAAI)

Respiratory

1. Indication

  • Target Patient: Immunotherapy is a therapeutic option for patients with Allergic Rhinitis and Bronchial Asthma who do not respond well to standard medication or want to alter the natural course of the disease.

    • 2. Treatment Modes

  • SCIT (Subcutaneous Immunotherapy): The most common method (used by 97% of Filipino allergists). It involves regular injections (allergy shots).
  • SLIT (Sublingual Immunotherapy): An alternative method using drops or tablets under the tongue (used by 67% of allergists).

    • 3. Management Protocol

  • Common Allergens: The most common triggers targeted are House Dust Mites (100% usage), followed by Cockroach, Animal Dander, and Pollen.
  • Duration: The recommended duration for effective treatment is typically 3 to 5 years.
  • Expected Relief: Most patients report feeling relief from symptoms within 6 to 8 months of starting therapy.
    • 🚨

    Warning Signs

    RISKS & SAFETY

  • Systemic Reactions: There is a risk of severe allergic reaction (anaphylaxis), especially with SCIT (injections).
  • Drop-out: Compliance is a major challenge; patients often stop due to the long duration (3-5 years) or cost.

    • Reference

    1. Maria Carmela A. Kasala, MD, et al. (PSAAI) (2024). The Practice of Allergen Immunotherapy among Allergists in the Philippines (Philippine Journal of Allergy, Asthma and Immunology).
    Back to all protocols